Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effects of Serelaxin in Patients with Acute Heart Failure

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A More COMPLETE Picture of Revascularization in STEMI

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Partial Oral Therapy for Osteomyelitis and Endocarditis. Reply

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic Potential of Intracardiac Echocardiography in Patients with Suspected Prosthetic Valve Endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Association between Type D personality and outcomes in patients with non-ischemic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • RELAX-AHF-2 Committees Investigators
View graph of relations

BACKGROUND: Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patients with acute heart failure.

METHODS: In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled patients who were hospitalized for acute heart failure and had dyspnea, vascular congestion on chest radiography, increased plasma concentrations of natriuretic peptides, mild-to-moderate renal insufficiency, and a systolic blood pressure of at least 125 mm Hg, and we randomly assigned them within 16 hours after presentation to receive either a 48-hour intravenous infusion of serelaxin (30 μg per kilogram of body weight per day) or placebo, in addition to standard care. The two primary end points were death from cardiovascular causes at 180 days and worsening heart failure at 5 days.

RESULTS: A total of 6545 patients were included in the intention-to-treat analysis. At day 180, death from cardiovascular causes had occurred in 285 of the 3274 patients (8.7%) in the serelaxin group and in 290 of the 3271 patients (8.9%) in the placebo group (hazard ratio, 0.98; 95% confidence interval [CI], 0.83 to 1.15; P = 0.77). At day 5, worsening heart failure had occurred in 227 patients (6.9%) in the serelaxin group and in 252 (7.7%) in the placebo group (hazard ratio, 0.89; 95% CI, 0.75 to 1.07; P = 0.19). There were no significant differences between the groups in the incidence of death from any cause at 180 days, the incidence of death from cardiovascular causes or rehospitalization for heart failure or renal failure at 180 days, or the length of the index hospital stay. The incidence of adverse events was similar in the two groups.

CONCLUSIONS: In this trial involving patients who were hospitalized for acute heart failure, an infusion of serelaxin did not result in a lower incidence of death from cardiovascular causes at 180 days or worsening heart failure at 5 days than placebo. (Funded by Novartis Pharma; RELAX-AHF-2 ClinicalTrials.gov number, NCT01870778.).

Original languageEnglish
JournalThe New England journal of medicine
Volume381
Issue number8
Pages (from-to)716-726
Number of pages11
ISSN0028-4793
DOIs
Publication statusPublished - 22 Aug 2019

    Research areas

  • Acute Disease, Aged, Blood Pressure/drug effects, Cardiovascular Diseases/mortality, Disease Progression, Double-Blind Method, Female, Heart Failure/drug therapy, Hospitalization, Humans, Incidence, Infusions, Intravenous, Male, Recombinant Proteins/adverse effects, Relaxin/adverse effects, Treatment Failure, Vasodilator Agents/adverse effects

ID: 58252686